PRAME has been identified as a potential candidate for immunotherapy, eliciting a strong immune reaction in patients with AML, chronic myelogenous leukaemia (CML), acute lymphoblastic leukaemia (ALL) and melanoma.19, 20, 21, 22 Currently, the efficacy of anti‐PRAME vaccines is being evaluated for PRAME‐positive tumours in a clinical study.23 Therefore, in this review article, we describe the role of PRAME in tumorigenesis. Here, PRAME is linked to acute myeloid leukemia.